|Bid||0.00 x 800|
|Ask||0.00 x 3000|
|Day's Range||16.15 - 16.65|
|52 Week Range||15.02 - 25.31|
|Beta (3Y Monthly)||1.74|
|PE Ratio (TTM)||8.43|
|Earnings Date||Feb 10, 2020 - Feb 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.36|
– Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial –
-- Results being presented today in a late-breaking presentation (abstract TH-PO1201) at Kidney Week 2019, the annual meeting of the American Society of Nephrology in Washington, D.C. Exelixis, Inc. (EXEL) announced today that its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has reported positive results from a phase 3 pivotal trial of esaxerenone, a product of the companies’ prior research collaboration, in patients with diabetic nephropathy. Esaxerenone is a novel mineralocorticoid receptor (MR) blocker identified during the prior research collaboration between Exelixis and Daiichi Sankyo and subsequently developed and commercialized by Daiichi Sankyo.
Exelixis (EXEL) delivered earnings and revenue surprises of 55.00% and 18.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Total Revenue of $271.7 Million, Cabozantinib Franchise Revenue of $191.8 Million - - GAAP Diluted EPS of $0.31, Non-GAAP Diluted EPS of $0.34 - - Conference Call and Webcast Tod
In this article we are going to estimate the intrinsic value of Exelixis, Inc. (NASDAQ:EXEL) by taking the foreast...
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Individuals invest in the stock market for a variety of reasons. New investors often buy growth stocks in the hopes of massive gains. Many will turn to known names such as Tesla (NASDAQ:TSLA) or Netflix (NASDAQ:NFLX). However, investors may open this position only after stocks like this have become well-known. By then, the significant gains have already occurred in most cases.To see outsized returns, investors have to buy before the companies become frequently discussed in the media. This typically involves looking for unknown or lesser-known growth stocks making gains while escaping the notice of the financial press. * 7 Beverage Stocks to Buy Now Fortunately, numerous stocks have benefitted from substantial growth over the last few years. Moreover, Wall Street expects these increases to continue for a long time to come. These seven under-the-radar stocks to buy have both a track record of growth and the ability to deliver outsized returns for years.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abiomed (ABMD)Source: Pavel Kapysh / Shutterstock.com Abiomed (NASDAQ:ABMD) makes medical devices that improve circulatory functions, including artificial hearts. The company came into existence in 1981 to implant the first artificial heart. However, most of their work focuses on improving the function of existing organs.ABMD stock has traded since 1987. However, the equity did not begin to trade like other growth stocks until 2014. ABMD sold in the $25 per share range in the fall of 2014. From there, it began a steady increase and spiked to almost $460 per share about a year ago. However, profit growth has stagnated as analysts predict only 0.8% for this year. As a result, Abiomed has since fallen back, and it trades at just over $160 per share today.Still, with the stock having lost 65% of its value, investors should consider ABMD when it finally stops falling. As things stand now, its forward price-to-earnings (PE) ratio has fallen to 33.55.Moreover, analysts forecast profit growth, which had averaged 63.91% per year over the last five years, to soon see massive growth again. Wall Street predicts 24% average annual earnings increases for the next five years. Once this begins to appear in the results, ABMD may resume its climb back to its all-time high, and maybe beyond. Exelixis (EXEL)Source: Shutterstock Exelixis (NASDAQ:EXEL) develops medicines used in the treatment of cancer. In the world of oncology treatment, most know them best for Cometriq, their drug to treat thyroid cancer.EXEL hit a high of just over $30 per share in early 2018. Since then, it has seen more downs than ups as profit levels have pulled back. Wall Street forecasts an earnings decline of 58.8% for the year. Profits decreased as revenues from the company's collaboration agreements fell. At the same time, expenses for research, personnel, marketing, and taxes increased. Today, EXEL stock trades at about $16 per share.However, that drop in profits, along with a downtrend, may soon create a buying opportunity. It now trades at just 14.5 times forward earnings. And this year's lower profit looks like an anomaly. Profits grew by an average of 86.64% per year over the last five years. While the next five years will not quite match that level, analysts still expect annual earnings growth to average 46% per year over the next five years. * 10 Tech Stocks to Buy Now for 2025 As the population ages, and the company develops new treatments, rising revenues and profits should help EXEL maintain its place among growth stocks. Five Below (FIVE)Source: Jonathan Weiss / Shutterstock.com Five Below (NASDAQ:FIVE) operates as a different kind of ultra-discounter than a Dollar Tree (NASDAQ:DLTR) or a Dollar General (NYSE:DG). As the name implies, Five Below sells its products for $5 or less. Unlike other counterparts, it also caters specifically to children and teens.FIVE stock traded as low as $28 per share in late 2015. Since then, it has risen steadily, peaking at $148.22 per share in April of this year. FIVE saw a pullback over the summer but still trades above $125 per share.Still, that looks like a healthy pullback as the equity trades at around 34.1 times forward earnings. Moreover, profit growth seems to make that valuation justifiable. Analysts expect earnings to grow by an average of 20.4% per year over the next five years.Furthermore, compared to other ultra-discounters, the company is just getting started. Five Below operates over 850 stores in 33 states. Despite its large footprint, it remains much smaller than other ultra-discounters. Dollar Tree and Dollar General each operate more than 15,000 stores across the country.The youth demographic may not support 15,000 stores. However, this implies FIVE stock can still benefit from expansion to areas not yet served and add more stores in states where it currently operates. This and a moderate PE ratio should deliver returns to longer-term investors over time. Parsley Energy (PE)Source: Shutterstock Parsley Energy (NYSE:PE) operates as an independent exploration and production (E&P) company. Although headquartered in Austin, it deals in properties in the Permian Basin of West Texas and southeastern New Mexico. At the end of 2018, the company reported 499 million barrels of proven reserves and production that averaged 109,000 barrels per day.The E&P sector remains volatile, and most equities in this sector tend not to remain growth stocks. However, PE stock has typically maintained its earnings increases through the ups and downs.Admittedly, at the current price of close to $17 per share, it trades well off of the late 2016 peak of just under $40 per share. However, twice over the last year, it has bounced after hitting the $14 per share level. This strongly indicates a limited downside to PE stock.Moreover, the profit picture also looks favorable, considering the industry in which it operates. Like most E&P firms, it reported a net loss in 2016. Despite that hiccup, earnings grew by an average of 48.73% per year over the last five years. Analysts forecast the next five years will show an average profit growth rate of 38.7% per year. Despite massive profit increases, the forward PE ratio stands at about 8. PE stock also trades below its book value. * 7 Funds to Buy If the Market Turns Sour Given the growth available at a low valuation, investors may have an excellent reason to take a chance on an otherwise risky E&P stock. Planet Fitness (PLNT)Source: Ken Wolter / Shutterstock.com With over 1,800 locations spread across all 50 states and four foreign countries, most Americans have likely driven by a Planet Fitness (NYSE:PLNT) location. Admittedly, investors do not typically think of fitness centers when looking for growth stocks. However, this company has quietly turned its industry on its head. In a world where gym memberships easily cost $40 per month or more, Planet Fitness offers memberships between $10 and $22.99 per month.Both customers and investors have reacted positively to this business model. PLNT stock, which traded below $20 per share as late as 2017, rose as high as $81.90 per share by the summer of 2019. It has since fallen to a level of around $58 per share.However, this pullback may offer a buying opportunity. The forward PE ratio now stands at around 31. Furthermore, analysts expect earnings growth to average 25.3% per year over the next five years. With a market cap of around $5.4 billion, and growth outside the U.S. beginning to take off, both the company and PLNT stock still should have significant room for growth. Pinnacle Financial Partners (PNFP)Source: Shutterstock Pinnacle Financial (NASDAQ:PNFP) is the parent company of Pinnacle Bank, a Nashville-based regional bank operating in the Southeast. This financial institution, which started in 2000 in Nashville, has gradually spread to 114 locations in four southeastern states. It has also become the number one bank for deposits in the Nashville area.Like most banks, the 2008 financial crisis hit PNFP stock hard. However, since 2010, Pinnacle Financial has made itself one of the better-performing growth stocks. It has risen from just below $9 per share to almost $70 per share since early 2017. The stock has struggled since then, declining to a low of just over $43 per share last December. Since that time, it has resumed its move higher and trades at about $56 per share.Wall Street forecasts profit growth of 11.2% this year and just 1.7% in fiscal 2020. However, for the next five years, they expect average annual earnings increases of 32.2%. With a forward PE ratio of around 10.5, it appears the PNFP stock price does not yet factor in this future growth. * 10 Tech Stocks to Buy Now for 2025 Pinnacle looks poised to continue its expansion across the Southeast. With a focus on development, a low multiple, and massive profit growth expected, PNFP stock appears positioned to profit investors in the coming years. XPO Logistics (XPO)Source: via XPO Logistics (Modified) XPO Logistics (NYSE:XPO) has become one of the largest logistics firms in the world. The Greenwich, Connecticut-based company employs around 100,000 people. It serves about 50,000 customers in 32 different countries. The company began in 1989, and it has grown to its current size largely through acquisitions.Growth stocks like XPO have benefitted from tremendous earnings increases over the last ten years, due in large part to e-commerce. Trading at just over $3 per share in 2009, it rose as high as $116.27 per share by September 2018. From there, it saw a massive decline, falling to as low as $45.73 per share in March. However, since that time, it has seen a steady recovery. XPO stock sells for about $73 per share as of the time of this writing.Despite the rebound, it remains a reasonably-priced equity. XPO stock supports a forward PE ratio of around 16.5. This seems like a low multiple considering that analysts forecast a 19.7% earnings increase this year. Over the next five years, they estimate average annual profit growth of 25.9%.This means investors still can profit from XPO stock. Despite the growth, the market cap is only about $6.8 billion. With e-commerce still in a growth mode, XPO Logistics stock should keep on trucking for the foreseeable future.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Beverage Stocks to Buy Now * 10 Groundbreaking Technologies Created by Universities * 5 Semiconductor Stocks Worth Your Time The post 7 Under-The-Radar Growth Stocks That Could Benefit New Investors appeared first on InvestorPlace.
Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.
Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio in combination with Inlyta gets positive CHMP recommendation for first-line treatment of advanced kidney cancer.
Exelixis, Inc. (NASDAQ:EXEL) is a stock with outstanding fundamental characteristics. When we build an investment...
[Editor's note: "10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar" was previously published in July 2019. It has since been updated to include the most relevant information available.]2019 has been a seemingly good year for the broad market, but take a closer look. That strength has been limited to large caps. In the last three months, the S&P 500 has gained 2.4%, while the Russell 2000 small cap index has given up 1.4% of its value. The S&P 600 small cap index, with an even smaller typical market cap, is down nearly 4% in the last month.The group-wide weakness of the recent past, however, doesn't necessarily portend more weakness for all of these names in the foreseeable future. Indeed, as investors seek to lock in profits on their more recognizable large-cap positions, it's small-cap stocks that are most likely to be viewed as oversold, undervalued opportunities.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Marijuana Stocks to Ride High on the Farm Bill With that as the backdrop, here's a rundown of ten up-and-coming stocks that could energize portfolios at a time when more familiar names have little left to give. Not all of these names will ring a bell. But, that's the point. Bunge (BG)Source: Shutterstock Odds are good you've eaten something within the past 24 hours that Bunge (NYSE:BG) helped put on your plate. The company is one of the biggest global suppliers of grains like corn and wheat, but it also sells fertilizers, milled products and edible oils like olive oil and coconut oil.It isn't stopping there though. At the same time it's addressing the world's food scarcity crisis by establishing facilities closer to where needs exist, Bunge is also taking aim at the burgeoning energy crises. It and oil giant BP (NYSE:BP) announced this week they'll be working on a bioenergy project that makes the pair the world's third-biggest sugarcane processor.It's all working. Though revenue growth has been and will remain modest, these are businesses that scale well. This year's expected per-share earnings of $3.65 are projected to reach $3.84 next year. Exelixis (EXEL)Source: Shutterstock Exelixis (NASDAQ:EXEL) is a small biopharma outfit primarily focused on the treatment of cancer. Its flagship product, Cabometyx, accounts for roughly 80% of the EXEL's business, while collaboration income makes up most of the remainder.Exelixis isn't stopping with the development of Cabometyx's underlying tyrosine kinase-inhibitor though. The same molecular formula is now the basis of several dozen different clinical trials -- including a couple of phase three tests -- most of which are being handled by other pharmaceutical companies that want to use Exelixis' cabozantinib in conjunction with another drug. * 10 Marijuana Stocks to Ride High on the Farm Bill It's not a recipe for a massive, one-off growth spurt. But EXEL has set the stage for years of potential double-digit sales and earnings growth. Teladoc Health (TDOC)Source: Shutterstock Teladoc Health (NYSE:TDOC) isn't a profitable company, but at its current pace of progress, there's a light at the end of the tunnel. This year's and enxt year's top line are expected to improve by nearly 25%. That improvement should shrink 2020's loss meaningfully.It's a business model whose time has not only come, but is a sign of the times. Teladoc Health, in simplest terms, let's patients receive medical attention online. Rather than having to go into a doctor's office, an internet-based conversation -- either video chatting or a voice call -- can get you the clinical medical attention you need. Teladoc's doctors can even write a prescription when necessary. Brooks Automation (BRKS)Source: Shutterstock It was inevitable. As improved computers in turn improved robotics, manufacturing organizations would increasingly automate their operations. Not only are robots cheaper than humans, they tend to fabricate more precise products.Enter Brooks Automation (NASDAQ:BRKS), which offers automation solutions manufactures want, and even need.The company has carved out a couple of niches in the most lucrative of industries. That is, Brooks caters specifically to semiconductor makers, and life sciences companies. Its Spartan Sorters, for instance, handle ultra-thin wafers used in high-end technologies, allowing the fabrication of electronics components in a perfectly dust-free environment that might otherwise compromise the functioning of that component. * 10 Marijuana Stocks to Ride High on the Farm Bill In the red just three years ago, Brooks has found a bullish (and profitable) groove, easily qualifying BRKS as one of the top up-and-coming stocks among small-cap names. Qorvo (QRVO)Source: Shutterstock Speaking of semiconductor technologies, add Qorvo (NASDAQ:QRVO) to the list of small cap stocks to mull. Whereas Brooks Automation makes a means of handling them, Qorvo makes the chips that need special care when handling.It's clearly not an Intel (NASDAQ:INTC). It's not even a Texas Instruments (NASDAQ:TXN). Don't let its small size fool you though. What Qorvo may not be a head turner, but it's got a diverse menu of technology products that serve industries ranging from automobiles to mobile devices to aerospace outfits to the nascent Internet of Things arena.The advent of 5G connections (and the subsequent Internet of Things era it will help usher in) appears to be a particularly strong opportunity for the company. Not only does Qorvo make some of the 5G components used in 5G handsets, it makes solutions for so-called 'smart homes' that will be monitored and managed using those ultra-high-speed connections. Graphic Packaging Holding Company (GPK)You don't likely know it, but it would be unusual if within the past week you hadn't seen, or even touched, something made by Graphic Packaging Holding Company (NYSE:GPK). The company makes a variety of packaging solutions, particularly for the food and beverage industries, but also manufactures cartons that can double as display solutions.It's hardly a riveting business, but it's one that lends itself to scaling up. And, Graphic Packaging has kept things interesting by doing just that. GPK shares jumped more than 7% on Tuesday in response to the company's second quarter earnings beat that was at least partially driven by last year's acquisition of PFP and part of Letica Foodservice, and partially driven by its relatively new status as an approved member of Amazon's Packaging Support and Supplier Network. * 10 Marijuana Stocks to Ride High on the Farm Bill The company also announced ts intention to buy Artistic Carton, setting up more scale for later this year and beyond. Arrow Electronics (ARW)Source: Shutterstock Add Arrow Electronics (NYSE:ARW) to your list of noteworthy up-and-coming stocks. Though this year is proving to be a tough one that's taken a toll on the stock's price, the company is expected to start growing in earnest again come next year.If you need an electronics component, or even a completely self-contained system on a circuit board, Arrow Electronics probably offers it. If not, it can find or even develop one. The company sells thousands of various amplifiers, converters, capacitors, sensors, switches and more. None of it is sexy, but all of it is marketable.And the tech industry has taken notice. Microsoft (NASDAQ:MSFT) recently deemed Arrow Electronics to be one of the technology sector's top providers of Microsoft-based solutions for 2019. Catalent (CTLT)Source: Shutterstock If you've ever wondered who makes the capsules and coatings that surround pills and then melt in your stomach, it's rarely the drug's actual manufacturer. A company called Catalent (NYSE:CTLT) supplies them.That's only a fraction of the drug-delivery solutions the company brings to the table though. Catalent also offers spray-drying technology to improve a medicine's solubility, beauty-related packaging and drug-development solutions just to name a few more. Its lineup largely consists of the things consumers take for granted, but couldn't live without.It's not a high-growth business. It's a company that saw explosive growth in 2017, though, that's still largely being overlooked. * 10 Marijuana Stocks to Ride High on the Farm Bill And that's a big mistake. Patient investors would have been rewarded with a 79% gain thus far in 2019. And, with its growing role in the field of gene therapies, similar upside may still be on the table. F.N.B. Corp (FNB)Source: Shutterstock It's certainly no threat to the likes of Bank of America (NYSE:BAC) or Wells Fargo (NYSE:WFC)… at least not yet. Regional bank F.N.B. Corp (NYSE:FNB) is still a name to respect though, and perhaps even invest in.F.N.B. Corp -- consumers in the northeastern part of the country know it better as First National Bank -- operates nearly 400 branches in seven different states, sporting an asset base in excess of $30 billion. That leaves the bank in something of a sweet spot, where it's got enough size to make use of its fiscal muscle, but isn't so big that it's crimped by the Fed's banking rules specifically taking aim at institutions that are 'too big to fail.'More important, F.N.B. is a steady-growth machine. Through a combination of acquisitions and smart execution, the company hasn't failed to grow operating income in any quarter since 2011. XPO Logistics (XPO)Source: Shutterstock One wouldn't think a logistics market that already included the likes of United Parcel Service (NYSE:UPS) and FedEx (NYSE:FDX) would even allow another player to take shape, let alone thrive.But XPO Logistics (NYSE:XPO) is doing something most enterprising newcomers to any market try to do. They're using their competition's sheer size against them, and leveraging technology to become a highly-nimble service provider for organizations that need very specific solutions. XPO is more of a supply chain consultant than a shipping company. It identifying where inefficiencies exist -- something FedEx and UPS haven't quite embraced.The company's results underscore the argument that XPO is one of a handful of up-and-coming stocks worth a closer look. Though revenue has only been growing at a single-digit pace, per-share earnings are expected to reach $3.86 this year, up from last year's $3.19, and then soar to $4.65 in 2020.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks to Ride High on the Farm Bill * 8 Biotech Stocks to Watch After the Q2 Earnings Season * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The post 10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar appeared first on InvestorPlace.